Drug:
Reaction: DISEASE PROGRESSION
20250101 - 20251231
No. 301 - 400
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 301 | 25086501 |
US |
||
Disease progression, |
||||
REVUMENIB, |
||||
| 302 | 25081600 |
CA |
20 | 2 |
Condition aggravated, Decreased appetite, Disease progression, Hepatitis A, Lacrimation increased, Abdominal pain upper, Cough, Cough, Dyspnoea, Eye pain, Nasopharyngitis, Nasopharyngitis, Nausea, Intentional product use issue, Intentional dose omission, Product leakage, |
||||
ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB, ADALIMUMAB-FKJP, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, |
||||
| 303 | 25080408 |
FR |
50 | 1 |
Inappropriate schedule of product administration, Disease progression, |
||||
GLOFITAMAB, OBINUTUZUMAB, |
||||
| 304 | 25080416 |
CN |
92 | 1 |
Disease progression, |
||||
GLOFITAMAB, |
||||
| 305 | 25080905 |
CA |
74 | 1 |
Disease progression, |
||||
| 306 | 25076963 |
ES |
||
Disease progression, |
||||
| 307 | 25077218 |
LT |
50 | 2 |
Disease progression, |
||||
BEVACIZUMAB, BEVACIZUMAB, BEVACIZUMAB, PACLITAXEL, PACLITAXEL, PACLITAXEL, CARBOPLATIN, CARBOPLATIN, TOPOTECAN, TOPOTECAN, |
||||
| 308 | 25077278 |
CN |
||
Disease progression, Drug ineffective for unapproved indication, |
||||
ETOPOSIDE, IFOSFAMIDE, CYTARABINE, |
||||
| 309 | 25077285 |
CN |
||
Disease progression, Drug ineffective for unapproved indication, |
||||
ETOPOSIDE, IFOSFAMIDE, CYTARABINE, |
||||
| 310 | 25077286 |
CN |
||
Disease progression, Drug ineffective for unapproved indication, |
||||
ETOPOSIDE, IFOSFAMIDE, CYTARABINE, |
||||
| 311 | 25077291 |
CN |
||
Disease progression, Drug ineffective for unapproved indication, |
||||
ETOPOSIDE, IFOSFAMIDE, CYTARABINE, |
||||
| 312 | 25077337 |
US |
43 | 2 |
Disease progression, |
||||
RIPRETINIB, |
||||
| 313 | 25077355 |
GB |
55 | 2 |
Disease progression, Lung consolidation, Interstitial lung disease, Pneumonitis, Respiratory failure, Lower respiratory tract infection, Influenza, Pulmonary embolism, Product use issue, Cytomegalovirus infection, |
||||
NINTEDANIB, |
||||
| 314 | 25077457 |
PK |
62 | 2 |
Asthenia, Disease progression, |
||||
BEVACIZUMAB, |
||||
| 315 | 25077501 |
EG |
55 | 2 |
Death, Disease progression, |
||||
PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF, |
||||
| 316 | 25077624 |
BD |
35 | 2 |
Disease progression, |
||||
RITUXIMAB, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, DOXORUBICIN, PREDNISONE, IFOSFAMIDE, CARBOPLATIN, ETOPOSIDE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, CISPLATIN, |
||||
| 317 | 25077651 |
GB |
73 | 1 |
Endocarditis, Disease progression, |
||||
RITUXIMAB, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN, VINCRISTINE SULFATE, PREDNISONE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, CISPLATIN, |
||||
| 318 | 25078734 |
CA |
29 | 1 |
Haemophagocytic lymphohistiocytosis, Disease progression, Hyperferritinaemia, Hypofibrinogenaemia, Lymphadenopathy, Pancytopenia, Pyrexia, Splenomegaly, Therapy non-responder, Therapeutic product ineffective, Product use in unapproved indication, |
||||
DEXAMETHASONE, DEXAMETHASONE 1.5 MG, ANAKINRA, CYCLOSPORINE, ELTROMBOPAG, ETOPOSIDE, HUMAN IMMUNOGLOBULIN G, HUMAN IMMUNOGLOBULIN G, TOCILIZUMAB, PREDNISONE, |
||||
| 319 | 25078819 |
CN |
||
Disease progression, Drug ineffective for unapproved indication, |
||||
ETOPOSIDE, IFOSFAMIDE, CYTARABINE, |
||||
| 320 | 25078907 |
ES |
1 | |
Renal failure, Disease progression, |
||||
SPARSENTAN, |
||||
| 321 | 25078941 |
JP |
39 | 2 |
Disease progression, Epilepsy, Cytokine release syndrome, Depressed level of consciousness, Immune effector cell-associated neurotoxicity syndrome, Cognitive disorder, Status epilepticus, Amnestic disorder, Pyrexia, COVID-19, Product label issue, |
||||
AXICABTAGENE CILOLEUCEL, |
||||
| 322 | 25079098 |
ES |
||
Disease progression, Scar, |
||||
MELPHALAN, MELPHALAN HYDROCHLORIDE, |
||||
| 323 | 25079107 |
ES |
||
Disease progression, Scar, |
||||
MELPHALAN, MELPHALAN HYDROCHLORIDE, |
||||
| 324 | 25079118 |
CN |
||
Disease progression, Drug ineffective for unapproved indication, |
||||
ETOPOSIDE, IFOSFAMIDE, CYTARABINE, |
||||
| 325 | 25079119 |
CN |
||
Disease progression, Drug ineffective for unapproved indication, |
||||
ETOPOSIDE, IFOSFAMIDE, CYTARABINE, |
||||
| 326 | 25079195 |
ES |
||
Disease progression, |
||||
| 327 | 25079213 |
JP |
42 | 2 |
Disease progression, Neutrophil count decreased, |
||||
AXICABTAGENE CILOLEUCEL, |
||||
| 328 | 25079412 |
JP |
70 | 1 |
Disease progression, Pneumonia, Platelet count decreased, |
||||
AXICABTAGENE CILOLEUCEL, |
||||
| 329 | 25079561 |
JP |
67 | 2 |
Disease progression, Cerebrovascular disorder, Depressed level of consciousness, Cognitive disorder, Cytokine release syndrome, Immune effector cell-associated neurotoxicity syndrome, Disturbance in attention, Pyrexia, |
||||
AXICABTAGENE CILOLEUCEL, |
||||
| 330 | 25079589 |
GB |
1 | |
Platelet count decreased, Disease progression, Myocardial infarction, Cytokine release syndrome, |
||||
| 331 | 25079765 |
CN |
60 | 2 |
Interstitial lung disease, Disease progression, Off label use, |
||||
HUMAN IMMUNOGLOBULIN G, HUMAN IMMUNOGLOBULIN G, METHYLPREDNISOLONE, METHYLPREDNISOLONE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, TOFACITINIB, TOFACITINIB, |
||||
| 332 | 25079766 |
CN |
60 | 2 |
Interstitial lung disease, Disease progression, Off label use, |
||||
HUMAN IMMUNOGLOBULIN G, HUMAN IMMUNOGLOBULIN G, METHYLPREDNISOLONE, METHYLPREDNISOLONE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, TOFACITINIB, TOFACITINIB, |
||||
| 333 | 25080210 |
PK |
59 | 2 |
Disease progression, |
||||
PERTUZUMAB, TRASTUZUMAB, |
||||
| 334 | 25071979 |
CH |
1 | |
Rectal cancer metastatic, Disease progression, |
||||
CAPECITABINE, BEVACIZUMAB, FLUOROURACIL, LEUCOVORIN CALCIUM, OXALIPLATIN, CETUXIMAB, IRINOTECAN HYDROCHLORIDE, AFLIBERCEPT, |
||||
| 335 | 25072067 |
IN |
53 | 2 |
Disease progression, |
||||
PERTUZUMAB, |
||||
| 336 | 25072075 |
HU |
||
Disease progression, Drug ineffective, |
||||
RITUXIMAB, POLATUZUMAB VEDOTIN, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, PREDNISONE, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, CYTARABINE, CISPLATIN, BENDAMUSTINE HCL, DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN, |
||||
| 337 | 25072233 |
CN |
64 | 1 |
Disease progression, |
||||
GLOFITAMAB, |
||||
| 338 | 25072347 |
US |
41 | 2 |
Disease progression, |
||||
BEVACIZUMAB, CAPECITABINE, FLUOROURACIL, OXALIPLATIN, FRUQUINTINIB, LISINOPRIL, LEVETIRACETAM, LEVETIRACETAM ORAL, LEVETIRACETAM INJECTION, LEVETIRACETAM IN SODIUM CHLORIDE, REGORAFENIB, |
||||
| 339 | 25072570 |
JP |
6 | 1 |
Drug eruption, Disease progression, Oedema peripheral, |
||||
TEPOTINIB HYDROCHLORIDE, CAPMATINIB, |
||||
| 340 | 25072681 |
CN |
63 | 1 |
Disease progression, Metastases to central nervous system, |
||||
BEVACIZUMAB, BEVACIZUMAB, CISPLATIN, CISPLATIN, |
||||
| 341 | 25073008 |
US |
70 | 2 |
Disease progression, Product odour abnormal, Drug ineffective, Erythema, |
||||
IVERMECTIN, |
||||
| 342 | 25073337 |
JP |
50 | 2 |
Disease progression, |
||||
PREGABALIN, CARBAMAZEPINE, |
||||
| 343 | 25073350 |
JP |
50 | 1 |
Disease progression, |
||||
TEMOZOLOMIDE, |
||||
| 344 | 25073371 |
CZ |
61 | 1 |
Therapeutic product effect incomplete, Disease progression, Neuropathy peripheral, |
||||
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM, FLUOROURACIL, FLUOROURACIL, OXALIPLATIN, |
||||
| 345 | 25073866 |
BR |
1 | |
Disease progression, |
||||
BELINOSTAT, |
||||
| 346 | 25073965 |
US |
15 | 1 |
Disease progression, |
||||
RISDIPLAM, |
||||
| 347 | 25074008 |
SE |
69 | 2 |
Herpes zoster, Urosepsis, Disease progression, |
||||
ATEZOLIZUMAB, ATEZOLIZUMAB, CARBOPLATIN, ETOPOSIDE, |
||||
| 348 | 25074016 |
CN |
61 | 1 |
Disease progression, |
||||
GLOFITAMAB, |
||||
| 349 | 25074038 |
GR |
||
Diffuse large B-cell lymphoma refractory, Disease progression, Off label use, Intentional product use issue, |
||||
RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, FILGRASTIM, FILGRASTIM, FILGRASTIM, FILGRASTIM, FILGRASTIM, VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR, VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR, ERYTHROPOIETIN, VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE, AMLODIPINE BESYLATE, AMLODIPINE BESYLATE, AMLODIPINE BESYLATE, AMLODIPINE BESYLATE, AMLODIPINE BESYLATE, CYTARABINE, CYTARABINE, CYTARABINE, CYTARABINE, CYTARABINE, METHYLPREDNISOLONE, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, VINCRISTINE SULFATE, VINCRISTINE SULFATE, VINCRISTINE SULFATE, VINCRISTINE SULFATE, VINCRISTINE SULFATE, CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE, ERYTHROPOIETIN, ERYTHROPOIETIN, ERYTHROPOIETIN, ERYTHROPOIETIN, ERYTHROPOIETIN, ALBUMIN HUMAN, ALBUMIN HUMAN, ALBUMIN HUMAN, ALBUMIN HUMAN, ALBUMIN HUMAN, CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE, CYTARABINE, CYTARABINE, DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN, DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN, DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN, DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN, DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, DOXORUBICIN, DOXORUBICIN, DOXORUBICIN, DOXORUBICIN, SPIRONOLACTONE, SPIRONOLACTONE, SPIRONOLACTONE, SPIRONOLACTONE, SPIRONOLACTONE, CISPLATIN, CISPLATIN, CISPLATIN, MEROPENEM, MEROPENEM, |
||||
| 350 | 25074187 |
JP |
83 | 2 |
Disease progression, |
||||
GEMCITABINE HYDROCHLORIDE, GEMCITABINE, CISPLATIN, |
||||
| 351 | 25074469 |
IT |
7 | 2 |
Rheumatoid arthritis-associated interstitial lung disease, Off label use, Drug ineffective for unapproved indication, Disease progression, |
||||
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, |
||||
| 352 | 25074498 |
US |
61 | 1 |
Disease progression, Drug ineffective, |
||||
ABIRATERONE ACETATE, ABIRATERONE, ABIRATERONE ACETATE, ABIRATERONE, |
||||
| 353 | 25075075 |
FR |
||
Disease progression, |
||||
TEBENTAFUSP, |
||||
| 354 | 25075219 |
CN |
66 | 2 |
Hepatic failure, Interstitial lung disease, Disease progression, Respiratory failure, Off label use, |
||||
HUMAN IMMUNOGLOBULIN G, HUMAN IMMUNOGLOBULIN G, METHYLPREDNISOLONE, METHYLPREDNISOLONE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, |
||||
| 355 | 25075469 |
CN |
37 | 1 |
Drug ineffective, Diffuse large B-cell lymphoma recurrent, Disease progression, Platelet count decreased, Immunoglobulins decreased, Blood potassium decreased, Pyrexia, |
||||
RITUXIMAB, RITUXIMAB, POLATUZUMAB VEDOTIN, POLATUZUMAB VEDOTIN, GLOFITAMAB, ETOPOSIDE, PREDNISONE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, DOXORUBICIN, BENDAMUSTINE HCL, ACALABRUTINIB, |
||||
| 356 | 25075751 |
JP |
8 | 1 |
Disease progression, Bacterial infection, Cognitive disorder, Cytokine release syndrome, Immune effector cell-associated neurotoxicity syndrome, Urinary incontinence, Pyrexia, Neutrophil count decreased, Platelet count decreased, |
||||
AXICABTAGENE CILOLEUCEL, TOCILIZUMAB, |
||||
| 357 | 25075760 |
JP |
6 | 1 |
Disease progression, Cytokine release syndrome, Pyrexia, |
||||
AXICABTAGENE CILOLEUCEL, |
||||
| 358 | 25075905 |
JP |
7 | 2 |
Disease progression, |
||||
AXICABTAGENE CILOLEUCEL, |
||||
| 359 | 25076326 |
CN |
66 | 2 |
Hepatic failure, Interstitial lung disease, Disease progression, Respiratory failure, Off label use, |
||||
HUMAN IMMUNOGLOBULIN G, HUMAN IMMUNOGLOBULIN G, METHYLPREDNISOLONE, METHYLPREDNISOLONE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, |
||||
| 360 | 25076559 |
ES |
1 | |
Disease progression, Palliative care, Bedridden, |
||||
| 361 | 25076563 |
ES |
1 | |
Myelosuppression, Drug ineffective, Drug interaction, Disease progression, |
||||
MIRTAZAPINE, LINEZOLID, LINEZOLID, LINEZOLID, LINEZOLID, PACLITAXEL, PACLITAXEL, PACLITAXEL, PACLITAXEL, PACLITAXEL, PEMETREXED, PEMETREXED DISODIUM, PEMETREXED, PEMETREXED DISODIUM, PEMETREXED, PEMETREXED DISODIUM, PEMETREXED, PEMETREXED DISODIUM, PEMETREXED, PEMETREXED DISODIUM, VINORELBINE, CARBOPLATIN, CARBOPLATIN, CARBOPLATIN, CARBOPLATIN, CARBOPLATIN, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, TRIMETHOPRIM, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, APIXABAN, ALPRAZOLAM, AZITHROMYCIN, AZITHROMYCIN MONOHYDRATE, AZITHROMYCIN DIHYDRATE, CEFTRIAXONE, CEFTRIAXONE SODIUM, AMIKACIN, |
||||
| 362 | 25078292 |
87 | 2 | |
Disease progression, |
||||
SOTORASIB, |
||||
| 363 | 25066113 |
US |
53 | 2 |
Disease progression, |
||||
FAM-TRASTUZUMAB DERUXTECAN-NXKI, FAM-TRASTUZUMAB DERUXTECAN-NXKI, |
||||
| 364 | 25066381 |
US |
||
Disease progression, |
||||
APALUTAMIDE, |
||||
| 365 | 25066384 |
LB |
||
Disease progression, |
||||
ATEZOLIZUMAB, |
||||
| 366 | 25066711 |
DE |
83 | 1 |
Disease progression, |
||||
SONIDEGIB, |
||||
| 367 | 25066754 |
PK |
62 | 2 |
Disease progression, |
||||
PERTUZUMAB, TRASTUZUMAB, |
||||
| 368 | 25066824 |
CN |
62 | 1 |
Disease progression, Metastases to diaphragm, |
||||
BEVACIZUMAB, CAPECITABINE, OXALIPLATIN, FLUOROURACIL, |
||||
| 369 | 25066914 |
CA |
33 | 1 |
Disease progression, |
||||
DOXORUBICIN, |
||||
| 370 | 25067342 |
CA |
63 | 1 |
Disease progression, |
||||
FLUCONAZOLE, |
||||
| 371 | 25067702 |
TR |
||
Disease progression, |
||||
SACITUZUMAB GOVITECAN, |
||||
| 372 | 25067830 |
FR |
12 | 2 |
Disease progression, Drug ineffective for unapproved indication, Fatigue, Therapy partial responder, |
||||
ETOPOSIDE, ETOPOSIDE, AXITINIB, AXITINIB, CARBOPLATIN, THIOTEPA, BEVACIZUMAB, |
||||
| 373 | 25067918 |
SE |
14 | 1 |
Disease progression, Drug ineffective, Drug ineffective for unapproved indication, |
||||
ETOPOSIDE, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, DOXORUBICIN, |
||||
| 374 | 25068095 |
FR |
14 | 1 |
Disease progression, Drug ineffective for unapproved indication, Thrombocytopenia, Proteinuria, Hypertension, Diarrhoea, |
||||
ETOPOSIDE, AXITINIB, BEVACIZUMAB, |
||||
| 375 | 25068108 |
FR |
14 | 2 |
Hypothyroidism, Disease progression, Drug ineffective for unapproved indication, Thrombocytopenia, Hypertension, Fatigue, Diarrhoea, Anaemia, |
||||
ETOPOSIDE, ETOPOSIDE, AXITINIB, CARBOPLATIN, THIOTEPA, BEVACIZUMAB, ABEMACICLIB, |
||||
| 376 | 25069236 |
FR |
65 | |
Drug ineffective, Disease progression, |
||||
FULVESTRANT, FULVESTRANT, RIBOCICLIB, RIBOCICLIB, |
||||
| 377 | 25069261 |
IT |
83 | 1 |
Drug ineffective, Disease progression, |
||||
PREDNISONE, BENDAMUSTINE HCL, RITUXIMAB, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, METHOTREXATE, METHOTREXATE SODIUM, |
||||
| 378 | 25069287 |
IT |
83 | 1 |
Disease progression, Drug ineffective, |
||||
PREDNISONE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, METHOTREXATE, METHOTREXATE SODIUM, |
||||
| 379 | 25069533 |
US |
||
Disease progression, |
||||
SECUKINUMAB, |
||||
| 380 | 25069656 |
US |
73 | 1 |
Disease progression, Drug ineffective, |
||||
ABIRATERONE ACETATE, ABIRATERONE, ABIRATERONE ACETATE, ABIRATERONE, PREDNISONE, PREDNISONE, |
||||
| 381 | 25069665 |
US |
33 | 1 |
Drug ineffective, Disease progression, Off label use, |
||||
ETOPOSIDE, DOXORUBICIN, PREDNISONE, IFOSFAMIDE, CARBOPLATIN, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CLADRIBINE, CYTARABINE, MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE, |
||||
| 382 | 25069676 |
US |
1 | |
Disease progression, Drug ineffective, |
||||
ABIRATERONE ACETATE, ABIRATERONE, ABIRATERONE ACETATE, ABIRATERONE, PREDNISONE, PREDNISONE, DOCETAXEL, DOCETAXEL ANHYDROUS, DOCETAXEL, DOCETAXEL ANHYDROUS, ENZALUTAMIDE, ENZALUTAMIDE, TESTOSTERONE, TESTOSTERONE,, TESTOSTERONE, TESTOSTERONE,, |
||||
| 383 | 25069677 |
US |
1 | |
Drug ineffective, Disease progression, |
||||
DOCETAXEL, DOCETAXEL ANHYDROUS, DOCETAXEL, DOCETAXEL ANHYDROUS, ABIRATERONE ACETATE, ABIRATERONE, ABIRATERONE ACETATE, ABIRATERONE, PREDNISONE, PREDNISONE, CABAZITAXEL, CABAZITAXEL, SIPULEUCEL-T, SIPULEUCEL-T, CARBOPLATIN, CARBOPLATIN, |
||||
| 384 | 25070239 |
US |
||
Lung adenocarcinoma stage IV, Disease progression, |
||||
CARBOPLATIN, CARBOPLATIN, IPILIMUMAB, IPILIMUMAB, NIVOLUMAB, NIVOLUMAB, PEMETREXED, PEMETREXED DISODIUM, PEMETREXED, PEMETREXED DISODIUM, |
||||
| 385 | 25070295 |
TR |
||
Disease progression, |
||||
SACITUZUMAB GOVITECAN, |
||||
| 386 | 25071024 |
RU |
63 | |
Metastases to central nervous system, Lung neoplasm, Lymphangiosis carcinomatosa, Atelectasis, Pleural effusion, Pericardial effusion, Disease progression, Hydrothorax, Metastases to liver, Kidney enlargement, Panniculitis, Bone lesion, Therapy partial responder, Liver injury, Hepatic steatosis, Mesenteric panniculitis, Metastases to bone, Pelvic fluid collection, Hydronephrosis, Nephrolithiasis, Ascites, Ureteric dilatation, Rib fracture, Procedural site reaction, Induration, Incision site swelling, |
||||
PERTUZUMAB, PERTUZUMAB, TRASTUZUMAB, TRASTUZUMAB, TRASTUZUMAB, TRASTUZUMAB, ADO-TRASTUZUMAB EMTANSINE, DOCETAXEL, DOCETAXEL ANHYDROUS, |
||||
| 387 | 25061271 |
PK |
||
Disease progression, |
||||
BLINATUMOMAB, |
||||
| 388 | 25061506 |
PK |
59 | 2 |
Disease progression, |
||||
TRASTUZUMAB, |
||||
| 389 | 25061511 |
CZ |
||
Hodgkin^s disease, Hodgkin^s disease refractory, Nephropathy toxic, Haematopoietic stem cell mobilisation, Disease progression, Haemoglobin abnormal, Platelet count abnormal, Blood lactate dehydrogenase abnormal, C-reactive protein abnormal, White blood cell count abnormal, Night sweats, Pyrexia, Intentional product use issue, |
||||
RITUXIMAB, BRENTUXIMAB VEDOTIN, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, DOXORUBICIN, ETOPOSIDE, GEMCITABINE HYDROCHLORIDE, GENTAMICIN, GENTAMICIN SULFATE, IFOSFAMIDE, PEMBROLIZUMAB, PREDNISONE, VINCRISTINE SULFATE, ETOPOSIDE PHOSPHATE, DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN, GENTAMICIN SULFATE, |
||||
| 390 | 25061683 |
ES |
45 | 2 |
Disease progression, Skin lesion, Pain, |
||||
| 391 | 25061760 |
AT |
||
Disease progression, Intentional product use issue, |
||||
BEVACIZUMAB, ATEZOLIZUMAB, CARVEDILOL, |
||||
| 392 | 25061948 |
US |
1 | |
Disease progression, |
||||
NIROGACESTAT, |
||||
| 393 | 25061989 |
US |
2 | |
Photopsia, Abdominal discomfort, Gastrointestinal disorder, Disease progression, |
||||
NIROGACESTAT, |
||||
| 394 | 25062258 |
CA |
1 | |
Retinal vein occlusion, Disease progression, |
||||
RANIBIZUMAB, |
||||
| 395 | 25062356 |
IN |
64 | 1 |
Disease progression, Hypertension, Haemoglobin decreased, |
||||
ATEZOLIZUMAB, |
||||
| 396 | 25062370 |
ES |
45 | 2 |
Disease progression, Toxicity to various agents, Mucosal inflammation, Palmar-plantar erythrodysaesthesia syndrome, |
||||
CAPECITABINE, VINORELBINE, DOXORUBICIN, CARBOPLATIN, CARBOPLATIN, |
||||
| 397 | 25062374 |
JP |
65 | 2 |
Disease progression, Drug resistance mutation, |
||||
BRIGATINIB, |
||||
| 398 | 25062529 |
US |
||
Disease progression, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
| 399 | 25062579 |
AT |
27 | 2 |
Infection, Spinal disorder, Disease progression, Maternal exposure before pregnancy, Pleocytosis, CSF oligoclonal band present, Anti-aquaporin-4 antibody positive, |
||||
NATALIZUMAB, RITUXIMAB, |
||||
| 400 | 25062964 |
JP |
9 | 1 |
Cerebral salt-wasting syndrome, Muscular weakness, Disease progression, |
||||
PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, METHOTREXATE, METHOTREXATE SODIUM, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, NELARABINE, NELARABINE INJECTION, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28